The vascular endothelium: A regulator of arterial tone and interface for the immune system

Critical Reviews in Clinical Laboratory Sciences

Volumn 54, Issue 7-8, 2017, Pages 458-470

  Khaddaj Mallat, Rayan ^a   Mathew John, Cini ^a   Kendrick, Dylan J ^a   Braun, Andrew P ^a  

^a LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

Author keywords

Endothelial dysfunction; immunity; KCa channel; microparticles; nitric oxide; vasodilation

Indexed keywords

VASOACTIVE AGENT; CARDIOVASCULAR AGENT; NITRIC OXIDE;

ADAPTIVE IMMUNITY; AGING; ANGIOGENESIS; ARTERY TONE; ATHEROSCLEROSIS; BLOOD FLOW; BLOOD VESSEL TONE; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CELLS BY BODY ANATOMY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL MICROPARTICLE; EXOSOME; FUNCTIONAL STATUS; HUMAN; HYPERTENSION; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; ISCHEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; TISSUE METABOLISM; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; ANIMAL; IMMUNOLOGY; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; VASOCONSTRICTION; VASODILATATION;

ANIMALS; CARDIOVASCULAR AGENTS; ENDOTHELIUM, VASCULAR; HUMANS; MICE; NITRIC OXIDE; RATS; VASOCONSTRICTION; VASODILATION;

EID: 85038240970     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.1080/10408363.2017.1394267     Document Type: Review

References (134)

1. Mulvany MJ, Aalkjaer C., Structure and function of small arteries. Physiol Rev. 1990;70:921–961.
2. Christensen KL, Mulvany MJ., Location of resistance arteries. J Vasc Res. 2001;38:1–12.
3. Segal SS., Regulation of blood flow in the microcirculation. Microcirculation. 2005;12:33–45.
4. Davis MJ, Hill MA, Kuo L., Local regulation of microvascular perfusion. In: Tuma RF, Duran WN, Ley K, editors. Handbook of physiology: microcirculation. Academic Press; 2008. pp. 161–284.
5. Bayliss WM., On the local reactions of the arterial wall to changes of internal pressure. J Physiol (Lond). 1902;28:220–231.
6. Johnson PC., The myogenic response. In: Bohr DF, Somylo AP, Sparks HV, editors. Handbook of physiology: the cardiovascular system, vascular smooth muscle. Vol. 2. American Physiological Society; 1980. pp. 409–442.
7. Davis MJ, Hill MA., Signaling mechanisms underlying the vascular myogenic response. Physiol Rev. 1999;79:387–423.
8. Pries AR, Kuebler W., Normal endothelium. Handbook of Experimental Pharmacology. 2006;176:1–40.
9. Sato M, Ohashi T., Biorheological views of endothelial cell responses to mechanical stimuli. Biorheology. 2005;42:421–441.
10. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res. 2007;100:158–173.
11. Westcott EB, Segal SS., Perivascular innervation: a multiplicity of roles in vasomotor control and myoendothelial signaling. Microcirculation. 2013;20:217–238.
12. Saltin B, Mortensen SP., Inefficient functional sympatholysis is an overlooked cause of malperfusion in contracting skeletal muscle. J Physiol (Lond). 2012;590:6269–6275.
13. Hearon CM, Jr, Dinenno FA., Regulation of skeletal muscle blood flow during exercise in ageing humans. J Physiol (Lond). 2016;594:2261–2273.
14. 2+ signals to oppose vasoconstriction of mouse mesenteric arteries. Am J Physiol Heart Circ Physiol. 2012;302:H594–H602.
15. Garland CJ, Bagher P, Powell C, et al. Voltage-dependent Ca2+ entry into smooth muscle during contraction promotes endothelium-mediated feedback vasodilation in arterioles. Sci Signal. 2017;10:eaal3806.
16. Thomas GD., Functional sympatholysis in hypertension. Auton Neurosci. 2015;188:64–68.
17. Chistiakov DA, Orekhov AN, Bobryshev YV., Endothelial barrier and its abnormalities in cardiovascular disease. Front Physiol. 2015;6:365.
18. Tietz S, Engelhardt B., Brain barriers: crosstalk between complex tight junctions and adherens junctions. J Cell Biol. 2015;209:493–506.
19. Mehta D, Ravindran K, Kuebler WM., Novel regulators of endothelial barrier function. Am J Physiol Lung Cell Mol Physiol. 2014;307:L924–L935.
20. Phng LK, Gerhardt H., Angiogenesis: a team effort coordinated by Notch. Dev Cell. 2009;16:196–208.
21. Yuan S, Kevil CG., Nitric oxide and hydrogen sulfide regulation of ischemic vascular remodeling. Microcirculation. 2016;23:134–145.
22. Wragg JW, Durant S, McGettrick HM, et al. Shear stress regulated gene expression and angiogenesis in vascular endothelium. Microcirculation. 2014;21:290–300.
23. Cora D, Astanina E, Giraudo E, et al. Semaphorins in cardiovascular medicine. Trends Mol Med. 2014;20:589–598.
24. Félétou M, Vanhoutte PM., EDHF: an update. Clin Sci. 2009;117:139–155.
25. Edwards G, Félétou M, Weston AH., Endothelium-derived hyperpolarising factors and associated pathways: a synopsis. Pflugers Arch. 2010;459:863–879.
26. + channels in normal and impaired EDHF-dilator responses - relevance to cardiovascular pathologies and drug discovery. Br J Pharmacol. 2009;157:509–526.
27. Vanhoutte PM, Shimokawa H, Félétou M, et al. Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol (Oxf). 2017;219:22–96.
28. + channels directly control agonist-evoked nitric oxide synthesis in human vascular endothelial cells. Am J Physiol Cell Physiol. 2007;293:C458–C467.
29. Várnai P, Hunyady L, Balla T., STIM and Orai: the long-awaited constituents of store-operated calcium entry. TIPS. 2009;30:118–128.
30. 2+ channels in cardiovascular disease. Curr Top Membr. 2013;71:209–235.
31. Earley S, Brayden JE., Transient receptor potential channels in the vasculature. Physiol Rev. 2015;95:645–690.
32. Sullivan MN, Earley S. TRP channel Ca(2+) sparklets: fundamental signals underlying endothelium-dependent hyperpolarization. Am J Physiol, Cell Physiol. 2013;305:C999–C1008.
33. Ledoux J, Taylor MS, Bonev AD, et al. Functional architecture of inositol 1,4,5-trisphosphate signaling in restricted spaces of myoendothelial projections. Proc Natl Acad Sci USA. 2008;105:9627–9632.
34. Ca channels, reducing arteriolar tone. Proc Natl Acad Sci USA. 2012;109:18174–18179.
35. 2+ signals through endothelial TRPV4 channels regulate vascular function. Science. 2012;336:597–601.
36. 2+ dynamics in swine coronary arteries. Circ Res. 2016;118:1078–1090.
37. Lückhoff A, Busse R., Calcium influx into endothelial cells and formation of endothelium-derived relaxing factor is controlled by the membrane potential. Pflugers Arch. 1990;416:305–311.
38. Busse R, Fichtner H, Lückhoff A, et al. Hyperpolarization and increased free calcium in acetylcholine-stimulated endothelial cells. Am J Physiol Heart Circ Physiol. 1988;255:H965–H969.
39. Busse R, Edwards G, Félétou M, et al. EDHF: bringing the concepts together. Trends Pharmacol Sci. 2002;23:374–380.
40. + channel in porcine coronary artery endothelium: relevance to EDHF. Br J Pharmacol. 2002;135:1133–1143.
41. + channel in porcine coronary endothelium: relevance to EDHF. Br J Pharmacol. 2002;137:1346–1354.
42. Ca channels enhance agonist-evoked endothelial nitric oxide synthesis and arteriolar dilation. FASEB J. 2009;23:1138–1145.
43. 2+ concentration in agonist-activated endothelial cells. Gen Physiol Biophysics. 1999;18:199–208.
44. Stankevicius E, Lopez-Valverde V, Rivera L, et al. Combination of Ca2+-activated K + channel blockers inhibits acetylcholine-evoked nitric oxide release in rat superior mesenteric artery. Br J Pharmacol. 2006;149:560–572.
45. Dalsgaard T, Kroigaard C, Misfeldt M, et al. Openers of small conductance calcium-activated potassium channels selectively enhance NO-mediated bradykinin vasodilatation in porcine retinal arterioles. Br J Pharmacol. 2010;160:1496–1508.
46. Ca channels enhances coronary flow in the hearts of type 2 diabetic rats. J Mol Cell Cardiol. 2014;72:364–373.
47. Brondum E, Kold-Petersen H, Simonsen U, et al. NS309 restores EDHF-type relaxation in mesenteric small arteries from type 2 diabetic ZDF rats. Br J Pharmacol. 2010;159:154–165.
48. Damkjaer M, Nielsen G, Bodendiek S, et al. Pharmacological activation of KCa3.1/KCa2.3 channels produces endothelial hyperpolarization and lowers blood pressure in conscious dogs. Br J Pharmacol. 2012;165:223–234.
49. Mishra RC, Mitchell JR, Gibbons-Kroeker C, et al. A pharmacologic activator of endothelial KCa channels increases systemic conductance and reduces arterial pressure in an anesthetized pig model. Vasc Pharmacol. 2016;79:24–31.
50. Davies PF., Flow-mediated endothelial mechanotransduction. Physiol Rev. 1995;75:519–560.
51. Vanhoutte PM, Zhao Y, Xu A, et al. Thirty years of saying NO: sources, fate, actions, and misfortunes of the endothelium-derived vasodilator mediator. Circ Res. 2016;119:375–396.
52. Ca channel in smooth muscle. Trends Pharmacol Sci. 2001;22:505–512.
53. Kyle BD, Braun AP., The regulation of BK channel activity by pre- and post-translational modifications. Front Physiol. 2014;5:316.
54. McDonald LJ, Murad F., Nitric oxide and cGMP signaling. Adv Pharmacol. 1995;34:263–275.
55. Quayle JM, Nelson MT, Standen NB., ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev. 1997;77:1165–1232.
56. Chauhan SD, Nilsson H, Ahluwalia M, et al. Release of C-type natriuretic peptide accountf for the biological activity of endothelium-derived hyperpolarizing factor. Proc Natl Acad Sci USA. 2003;100:1426–1431.
57. Gauthier KM, Goldman DH, Aggarwal NT, et al. Role of arachidonic acid lipoxygenase metabolites in acetylcholine-induced relaxations of mouse arteries. Am J Physiol Heart Circ Physiol. 2011;300:H725–H735.
58. Campbell WB, Fleming I., Epoxyeicosatrienoic acide and endothelium-dependent responses. Pflugers Arch - Eur J Physiol. 2010;459:881–895.
59. Shimokawa H., Hydrogen peroxide as an endothelium-derived hyperpolarizing factor. Pflugers Arch. 2010;459:915–922.
60. Ellinsworth DC, Sandow SL, Shukla N, et al. Endothelium-derived hyperpolarization and coronary vasodilation: diverse and integrated roles of epoxyeicosatrienoic acides, hydrogen peroxide, and gap junctions. Microcirculation. 2015;23:15–32.
61. Ca. Am J Physiol Heart Circ Physiol. 2009;297:H1H9.
62. Gimbrone MA, Garcia CG., Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118:620–636.
63. De Meyer GR, Herman AG., Vascular endothelial dysfunction. Prog Cardiovasc Dis. 1997;34:325–342.
64. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840–844.
65. Cohen RA, Tong X., Vascular oxidative stress: The common link in hypertensive and diabetic vascular disease. J Cardiovasc Pharmacol. 2010;55:308–316.
66. Förstermann U., Nitric oxide and oxidative stress in vascular disease. Pflugers Arch. 2010;459:923–939.
67. Montezano AC, Dulak-Lis M, Tsiropoulou S, et al. Oxidative stress and human hypertension: Vascular mechanisms, biomarkers, and novel therapies. Can J Cardiol. 2015;31:631–641.
68. Ignarro LJ, Cirino G, Casini A, et al. Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol. 1999;34:879–886.
69. Calles-Escandon J, Cipolla M., Diabetes and endothelial dysfunction: a clinical perspective. Endocrine Rev. 2001;22:36–52.
70. Creager MA, Lüscher TF, Cosentino F, et al. Diabetes and vascular disease. Pathophysiology, clinical consequences and medical therapy: part I. Circ. 2003;108:1527–1532.
71. De Vriese AS, Verbeuren TJ, Van de Voorde J, et al. Endothelial dysfunction in diabetes. Br J Pharmacol. 2000;130:963–974.
72. Potenza MA, Gagliardi S, Nacci C, et al. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem. 2009;16:94–112.
73. Singh R, Barden A, Mori T, et al. Advanced glycation end-products: a review. Diabetologia. 2001;44:129–146.
74. Goldin A, Beckman JA, Schmidt AM, et al. Advanced glycation end products. Sparking the development of diabetic vascular injury. Circ. 2006;114:597–605.
75. Brownlee M., Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820.
76. Beckman JA, Paneni F, Cosentino F, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J. 2013;34:2444–2456.
77. Shimokawa H., Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol. 1999;31:23–37.
78. Paneni F, Beckman JA, Creager MA, et al. Diabetes and vascular disease: pathophysiology, clinical consequences and medical therapy: part I. Eur Heart J. 2013;34:2436–2446.
79. Gates PE, Strain WD, Shore AC., Human endothelial function and microvascular ageing. Exp Physiol. 2009;94:311–316.
80. Muller-Delp JM, Gurovich AN, Christou DD, et al. Redox balance in the aging microcirculation: New friends, new foes, and new clinical directions. Microcirculation. 2012;19:19–28.
81. Baschschmid MM, Schildknecht S, Matsui R, et al. Vascular aging: chronic oxidative stress and impairment of redox signaling-consequences for vascular homeostasis and disease. Ann Med. 2013;45:17–36.
82. Criqui MH, Aboyans V., Epidemiology of peripheral artery disease. Circ Res. 2015;116:1509–1526.
83. Donato AJ, Morgan RG, Walker AE, et al. Cellular and molecular biology of aging endothelial cells. J Mol Cell Cardiol. 2015;89:122–135.
84. Gutterman DD, Chabowski DS, Kadlec AO, et al. The human microcirculation: regulation of flow and Beyond Circ Res. 2016;118:157–172.
85. Bagher P, Segal SS., Regulation of blood flow in the microcirculation: role of conducted vasodilation. Acta Physiol (Oxf). 2011;202:271–284.
86. + channel activation. Artherioscler Thromb Vasc Biol. 2013;33:1892–1901.
87. 2+ influx and cell death induced by hydrogen peroxide. J Physiol. 2015;593:2155–2169.
88. Boerman EM, Everhart JE, Segal SS., Advanced age decreased local calcium signaling in endothelium of mouse mesenteric arteries in vivo. Am J Physiol Heart Circ Physiol. 2016;310:H1091–H1096.
89. Félétou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol. 2006;291:H985–H1002.
90. Koltsova EK, Ley K., How dendritic cells shape atherosclerosis. Trends Immunol. 2011;32:540–547.
91. Tuttolomondo A, Di Raimondo D, Pecoraro R, et al. Atherosclerosis as an inflammatory disease. Curr Pharm Des. 2012;18:4266–4288.
92. Schulz C, Massberg S., Platelets in atherosclerosis and thrombosis. Handb Exp Pharmacol. 2012;210:111–133.
93. Bogdan C., Nitric oxide synthase in innate and adaptive immunity: an update. Trends Immunol. 2015;36:161–178.
94. Wolllard KJ., Immunological aspects of atherosclerosis. Clin Sci. 2013;125:221–235.
95. Pober JS, Sessa WC., Evolving functions of endothelial cells in inflammation. Nat Rev Immunol. 2007;7:803–815.
96. Danese S, Dejana E, Fiocchi C., Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation. J Immunol. 2007;178:6017–6022.
97. Witztum JL, Lichtman AH., The influence of innate and adaptive immune responses on atherosclerosis. Annu Rev Pathol Mech Dis. 2014;9:73–102.
98. Mann DL. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res. 2011;108:1133–1145.
99. Stokes KY., Microvascular responses to hypercholesterolemia: the interactions between innate and adaptive immune responses. Antioxidants and Redox Signaling. 2006;8:1141–1151.
100. Di Marco E, Gray SP, Jandeleit-Dahm K., Diabetes alters activation and repression of pro- and anti-inflammatory signaling pathways in the vasculature. Front Endocrinol. 2013;4:68.
101. Mai J, Virtue A, Shen J, et al. An evolving new paradigm: endothelial cells - conditional innate immune cells. J Hematol Oncol. 2013;6:61.
102. Spirig R, Tsui J, Shaw S., The emergingn role of TLR and innate immunity in cardiovascular disease. Cardiol Res Pract. 2012;2012:1–12.
103. Busse R, Fleming I, Hecker M., Signal transduction in endothelium-dependent vasodilatation. Eur Heart J. 1993;14 (suppl.1):2–9.
104. Ley K, Laudanna C, Cybulsky MI, et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7:678–689.
105. Morawietz H. LOX-1 and atherosclerosis: proof of concept in LOX-1-knockout mice. Circ Res. 2007;100:1534–1536.
106. Chaplin DD., Overview of the immune response. J Allergy Clin Immunol. 2010;125:S3–S23.
107. McEver RP., Selectins: initiators of leucocyte adhesion and signalling at the vascular wall. Cardiovasc Res. 2015;107:331–339.
108. Ley K, Miller YI, Hedrick CC., Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol. 2011;31:1506–1516.
109. Berezin A, Zulli A, Kerrigan S, et al. Predictive role of circulating endothelial-derived microparticles in cardiovascular diseases. Clin Biochem. 2015;48:562–568.
110. Jansen F, Nickenig G, Werner N., Extracellular vesicles in cardiovascular disease. Potential applications in diagnosis, prognosis and epidemiology. Circ Res. 2017;120:1649–1657.
111. Koga H, Sugiyama S, Kugiyama K, et al. Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2005;45:1622–1630.
112. Sabatier F, Darmon P, Hugel B, et al. Type 1 and Type 2 diabetic patients display different patterns of cellular microparticles. Diabetes. 2002;51:2840–2845.
113. Gyorgy B, Szabo TG, Pasztoi M, et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci. 2011;68:2667–2688.
114. Martinez MC, Andriantsitohaina R., Extracellular vesicles in metabolic syndrome. Circ Res. 2017;120:1674–1686.
115. Lovren F, Verma S., Evolving role of microparticles in the pathophysiology of endothelial dysfunction. Clin Chem. 2013;59:1166–1174.
116. Schiro A, Wilkinson FL, Weston R, et al. Endothelial microparticles as conveyors of information in atherosclerotic disease. Atherosclerosis. 2014;234:295–302.
117. Boulanger C, Loyer X, Rautou PE, et al. Extracellular vesicles in coronary artery disease. Nat Rev Cardiol. 2017;14:259–272.
118. Triggle CR, Ding H., Endothelial dysfunction in diabetes: multiple targets for treatment. Pflugers Arch. 2010;459:977–994.
119. Anderson TJ, Charbonneau F, Title LM, et al. Microvascular function predicts cardiovascular events in primary prevention. Long-term results from the firefighters and their endothelium (FATE) study. Circ. 2011;123:163–169.
120. Hadi HAR, Al Suwaidi J., Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag. 2007;3:853–876.
121. Tang EH, Vanhoutte PM., Endothelial dysfunction: a strategic target in the treatment of hypertension? Pflügers. Pflugers Arch. 2010;459:995–1004.
122. Tousoulis D, Papageorgiou N, Androulakis E, et al. Diabetes mellitus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches. J Am Coll Cardiol. 2013;62:667–676.
123. Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis. 1995;38:87–104.
124. Kubes P, Suzuki M, Granger DN., Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA. 1991;88:4651–4655.
125. Furchgott RF., The role of endothelium in the responses of vascular smooth muscle to drugs. Annu Rev Pharmacol Toxicol. 1984;24:175–197.
126. Rhaleb NE, Yang XP, Carretero OA., The kallikrein-kinin system as a regulator of cardiovascular and renal function. Compr Physiol. 2011;1:971–993.
127. Oeseburg H, Iusuf D, van der Harst P, et al. Bradykinin protects aginst oxidative stress-induced endothelial cell senescence. Hypertension. 2009;53:417–422.
128. Mitchell JA, Ali F, Bailey L, et al. Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium. Exp Physiol. 2007;93:141–147.
129. Blanco-Rivero J, Cachofeiro V, Lahera V, et al. Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats. Hypertension. 2005;46:107–112.
130. Félétou M, Huang Y, Vanhoutte PM., Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol. 2011;164:894–912.
131. Behrendt D, Ganz P. Endothelial function. From vascular biology to clinical applications. Am J Cardiol. 2002;90:40L–48L.
132. Spiecker M, Liao JK., Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys. 2005;433:413–420.
133. Thorin E, Webb DJ., Endothelium-derived endothelin-1. Pflugers Arch. 2010;459:951–958.
134. Javeshghani D, Barhoumi T, Idris-Khodja N, et al. Reduced macrophage-dependent inflammation improves endothelin-1-induced vascular injury. Hypertension. 2013;62:112–117.